Distribution of ESBL-producing enterobacteria associated to community-acquired monomicrobial urinary tract infections and antimicrobial susceptibility trends over a 9-year period

Journal of Chemotherapy

Volumn 24, Issue 3, 2012, Pages 178-181

  Dias, Vanessa Cordeiro ^a,b   da Silva, Vânia Lúcia ^a   Firmo, Eduarda de Oliveira ^a   Bastos, Lucas Quinet de Andrade ^b   Bastos, André Netto ^b   Bastos, Ricardo Villela ^b   Diniz, Cláudio Galuppo ^a  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^b Cortes Villela Clinical Laboratory ^*  (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; NITROFURANTOIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATION; BRAZIL; CLINICAL EVALUATION; COMMUNITY ACQUIRED MONOMICROBIAL URINARY TRACT INFECTION; CONTROLLED STUDY; DISK DIFFUSION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; TREND STUDY; URINALYSIS; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; COMMUNITY-ACQUIRED INFECTIONS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; RISK FACTORS; TIME FACTORS; URINARY TRACT INFECTIONS;

EID: 84866254643     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000006     Document Type: Article

References (20)

1. Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of common urinary tract infections in JNMC Hospital Aligarth, India. Ann Clin Microbiol Antimicrob. 2007;6:1476-86.
2. Biswas D, Gupta P, Prasad R, Singh V, Arya M, Kumar A. Choice of antibiotic for empirical therapy of acute cystitis in a setting of high antimicrobial resistance. Indian J Med Sci. 2006;60(2):53-8.
3. Kahan NR, Chinitz DP, Waitman DA, Dushnitzky D, Kahan E, Shapiro M. Empiric treatment of uncomplicated urinary tract infection with fluoroquinolones in older women in Israel: another lost treatment option? Ann Pharmacother. 2006;40(12):2223-7.
4. Tankhiwale SS, Jalgaonkar SV, Ahamad S, Hassani U. Evaluation of extended spectrum beta lactamase in urinary isolates. Indian J Med Res. 2004;120(6):553-6.
5. Manges AR, Natarajan P, Solberg OD, Dietrich PS, Riley LW. The changing prevalence of drug-resistant Escherichia coli clonal groups in a community: evidence for community outbreaks of urinary tracts infections. Epidemiol Infect. 2006;134(2):425-31.
6. Tofteland S, Haldorsen B, Dahl KH, Simonsen GS, Steinbakk M, Walsh TR, et al. Effects of phenotype and genotype on methods for detection of extended-spectrum-b-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J Clin Microbiol. 2007;45(1):199-205.
7. Pitout, JDD, Nordmann, P, Laupland, KB, Poirel, L. Emergence of Enterobacteriaceae producing extended-spectrum b-lactamases (ESBLs) in the community. J Antimicrob Chemother. 2005;56(1):52-9.
8. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis. 1998;10(4):867-78.
9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Wayne: CLSI; 2011. 21th Informational Supplement Document M100-S21.
10. Paterson DL, Bonomo RA. Extended-spectrum b-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657-86.
11. Meier S, Weber R, Zbinden R, Ruef C, Hasse B. Extendedspectrum b-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection. 2011;39(4):333-40.
12. Arpin C, Dubois V, Maugein J, Jullin J, Dutilh B, Brochet JP, et al. Clinical and molecular analysis of extended spectrum blactamase producing enterobacteria in the community setting. J Clin Microbiol. 2005;43(10):5048-54.
13. Minarini LA, Gales AC, Palazzo ICV, Darini ALC. Prevalence of community-occurring extended spectrum beta-lactamaseproducing Enterobacteriaceae in Brazil. Curr Microbiol. 2007;54(5):335-41.
14. Randrianirina F, Vedy S, Rakotovao D, Ramarokoto CE, Ratsitohaina H, Carod JF, et al. Role of contaminated aspiration tubes in nosocomial outbreak of Klebsiella pneumoniae producing SHV-2 and CTX-m-15 extended-spectrum blactamases. J Hosp Infect. 2009;72(1):23-9.
15. Calbo E, Romaní V, Xercavins M, Gómez L, Vidal CG, Quintana S, et al. Risk factors for community onset urinary tract infections due to Escherichia coli harbouring extended-spectrum b-lactamases. J Antimicrob Chemother. 2006;57(4):780-3.
16. Nogueira KS, Higuti IH, Nascimento AJ, Terasawa LB, Oliveira S, Matos AP, et al. Occurence of extended-spectrum beta-lactamases in Enterobactereaceae isolated from hospitalized patientes in Curitiba, sourthern Brazil. Braz J Infect Dis. 2006;10(6):390-5.
17. Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A, Fadda G. Occurrence of extended-spectrum b-lactamases in Italy:implications for resistance to b-lactams and other antimicrobial drugs. Antimicrob Agents Chemother. 2002;46(1):196-202.
18. Yu WL, Chuang CM, Rasmussen JW. Extended-spectrum beta lactamases in Taiwan: epidemiology, detection, treatment and infection control. J Microbiol Immunol Infect. 2006;39(4):264-77.
19. Chong YP, Choi SH, Kim ES, Song EH, Lee EJ, Park KH, et al. Bloodstream infections caused by qnr-positive Enterobacteriaceae: clinical and microbiologic characteristics and outcomes. Diagn Microbiol Infect Dis. 2010;67(1):70-7.
20. Mody RM, Erwin D, Summers AM, Carrero HA, Selby EB, Ewell AJ, et al. Ertapenem susceptibility of extended-spectrum beta-lactamase-producing organisms. Ann Clin Microbiol Antimicrob. 2007;6:6.